ArticleArchives of microbiology2025
Synergistic antibacterial and antibiofilm properties of lupinifolin in combination with antibiotics against pathogenic bacteria.
Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Temporin-GHa-derived peptides enhance the antibacterial and antibiofilm activities of polymyxin B against Pseudomonas aeruginosa and Escherichia coli.Archives of microbiology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lupinifolin possesses the capability to combat specific pathogenic bacteria. Nonetheless, Gram-negative bacteria exhibit minimal inhibition by lupinifolin. This study evaluated the synergistic antibacterial and antibiofilm activities of combinations of lupinifolin and antibiotics against pathogenic bacteria using a checkerboard assay and time-kill analysis. Crystal violet staining and confocal laser scanning microscopy (CLSM) were utilized to evaluate antibiofilm properties. After treatment, gene expression changes in isolates were evaluated using quantitative real-time PCR. Lupinifolin and streptomycin synergistically inhibited MRSA and VRE with a FIC index of 0.5, whereas lupinifolin and vancomycin similarly inhibited S. aureus ATCC25923. Partially synergistic interaction against E. faecalis ATCC29212 between lupinifolin and tetracycline, vancomycin, and chloramphenicol with an FIC index of 0.625, 0.5625, and 0.625, respectively. Partially synergistic interaction against E. faecium HTY0256 between lupinifolin and tetracycline with an FIC index of 0.625. The interaction between lupinifolin and streptomycin against Gram-negative bacteria, such as E. coli ATCC25922, showed a synergistic effect. The time-kill assay of the combinations showed an inhibitory effect of more than 3 log and 2 log (CFU/ml) at 4 h incubation. CLSM revealed that the combinations reduced biofilm formation. The combination of lupinifolin and streptomycin altered biofilm-forming genes in E. faecalis ATCC29212 and VRE isolates; gelE and bepA were down-regulated. In contrast, MRSA isolates had sarA and ebpS up-regulated. In addition, our findings suggested that lupinifolin destroys cell membranes, as demonstrated by the expression of secA. Our investigation enabled the prospective integration of lupinifolin with antibiotics, enhancing their efficacy and application against antimicrobial-resistant pathogens.
Indexed as
Identifiers
41264017What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.